Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 9/20 | 0.53 |
| ▸ | MMP8 | P22894 | 2/20 | 0.52 |
| ▸ | ANPEP | P15144 | 2/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14123093 | 0.91 | CAPN1 (0.61) | CAPN1MMP8CTSBCAPN9MAPK1 | |
| SCHEMBL14123222 | 0.90 | MMP8 (0.53) | CAPN1MMP8ANPEPCTSBCAPN9 | |
| SCHEMBL29468187 | 0.89 | ITGB1 (0.49) | MMP8ANPEPCTSBCTSLMMP2 | |
| SCHEMBL15579525 | 0.88 | HDAC3 (0.53) | CAPN1MMP8ANPEPCTSBCAPN9 | |
| SCHEMBL14123115 | 0.88 | CAPN1 (0.54) | CAPN1MMP8ANPEPCTSBCAPN9 | |
| SCHEMBL14123116 | 0.88 | CAPN1 (0.56) | CAPN1MMP8ANPEPCTSBCAPN9 | |
| SCHEMBL14122945 | 0.88 | CAPN1 (0.56) | CAPN1MMP8ANPEPCTSBCAPN9 | |
| SCHEMBL14123225 | 0.87 | CAPN1 (0.51) | CAPN1MMP8ANPEPCTSBCAPN9 | |
| SCHEMBL14122814 | 0.87 | CAPN1 (0.66) | CAPN1MMP8CTSBCAPN9MAPK1 | |
| SCHEMBL14123169 | 0.86 | CAPN1 (0.56) | CAPN1MMP8CTSBCAPN9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673904-B2 | Epoxide inhibitors of cysteine proteases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673904-B2 | Epoxide inhibitors of cysteine proteases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| US-20080176841-A1 | EPOXIDE INHIBITORS OF CYSTEINE PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080176841-A1 | EPOXIDE INHIBITORS OF CYSTEINE PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176841-A1 | EPOXIDE INHIBITORS OF CYSTEINE PROTEASES | SERPINB1, EPHX1, EPX | CAPN1 199/4885MMP8 163/4885ANPEP 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.